Pharmaceutical Technology2h
Boehringer seeks approval of lung disease drug after second Phase III success
Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.
Pharmaceutical Technology3h
Public health strategies skip patients with rare diseases, says UK study
A study led by UCL found that individuals with rare diseases were five times more likely to die from Covid-19 than the ...
Pharmaceutical Technology8h
Keymed’s Stapokibart approved by NMPA for seasonal allergic rhinitis
China's NMPA has granted approval for Keymed Biosciences’ supplemental NDA of Stapokibart to treat seasonal allergic rhinitis ...
Pharmaceutical Technology10h
Super Bowl ad for copycat weight loss drugs stokes pharma power debate
Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...
Pharmaceutical Technology11h
Fourth person receives eGenesis’ gene-edited pig kidney transplant
A 66-year-old man has become the fourth person in the world to receive a genetically edited pig kidney transplant, performed ...
Pharmaceutical Technology12h
Eton secures US patent for diabetes insipidus treatment
Eton has secured a patent from the USPTO for its ET-600 product candidate’s desmopressin oral solution formulation for ...
Pharmaceutical Technology14h
FDA approves AbbVie’s Emblaveo for intra-abdominal infections
AbbVie has received US FDA approval for Emblaveo to be used in conjunction with metronidazole for individuals with cIAI.